Cargando…

T202. THE EFFECT OF ANTIPSYCHOTIC DRUGS ON MEMBRANE FUSION: AN IN VITRO STUDY

BACKGROUND: Common clinical use of antipsychotics (AP) drugs shows that their therapeutic mode of action still needs further clarification although it is admitted that the Dopamine receptor D2 (D2R) antagonism plays a significant role. For instance, clozapine (CLOZ) - which is known to be the most e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adrien, Vladimir, Fumat, Hugo, Tessier, Cédric, Nuss, Philippe, Tareste, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session III
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234619/ http://dx.doi.org/10.1093/schbul/sbaa029.762

Ejemplares similares

M10. SERUM AND CLINICAL MARKERS ASSOCIATED WITH MEMBRANE PUFA CONTENT IN A POPULATION OF STABILISED AND TREATED SCHIZOPHRENIA OUTPATIENTS
por: Bosc, Nicolas, et al.
Publicado: (2020)

Higher stress response and altered quality of life in schizophrenia patients with low membrane levels of docosahexaenoic acid
por: Adrien, Vladimir, et al.
Publicado: (2023)

T174. ANTIPSYCHOTICS AND THE MICROBIOME
por: Chen, Anderson, et al.
Publicado: (2020)

T6. ASSOCIATION BETWEEN THE USE OF AN ANTIPSYCHOTIC DRUG AND CHANGES IN LIPID PROFILE: A META-ANALYSIS
por: Brierley, Beverley, et al.
Publicado: (2020)

T200. METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS – PROTOCOL OF A SYSTEMATIC REVIEW AND NETWORK- METAANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2020)

T213. TREND OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS USE IN ASIA: FINDINGS FROM REAP ANTIPSYCHOTIC STUDIES
por: Lin, Shih-Ku, et al.
Publicado: (2020)

T206. ANTIPSYCHOTIC EFFECTIVENESS FOCUSING ON INSIGHT
por: Stabell, Lena, et al.
Publicado: (2020)

T8. ANTIPSYCHOTIC TREATMENT AND EYE MOVEMENT ABNORMALITIES IN SCHIZOPHRENIA
por: Takahashi, Junichi, et al.
Publicado: (2020)

T42. HIGH ADHERENCE TO CURRENT ANTIPSYCHOTIC AND ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL TO EVALUATE THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
por: Abbs, Brandon, et al.
Publicado: (2020)

T45. THE EFFICACY AND HETEROGENEITY OF ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA: A META-ANALYSIS
por: McCutcheon, Rob, et al.
Publicado: (2020)

T199. 7% WEIGHT CHANGE ASSOCIATED WITH ANTIPSYCHOTICS: A META-ANALYSIS
por: Crins, Joost, et al.
Publicado: (2020)

T216. VARIATION IN SIDE EFFECTS TO ANTIPSYCHOTIC TREATMENT ACROSS SCHIZOPHRENIA SPECTRUM DISORDERS
por: Susanne Neumeier, Maria, et al.
Publicado: (2020)

T167. QUALITATIVE DIFFERENCES IN LONG ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS AMONG SCHIZOPHRENIA PATIENTS
por: Karakasi, Valeria, et al.
Publicado: (2020)

T215. THE ANTIPSYCHOTIC ACTION OF HALOPERIDOL IN PSYCHOTIC-LIKE RATS REQUIRES PRESYNAPTIC VESICULAR ACCUMULATION
por: Müller, Christian, et al.
Publicado: (2020)

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

T211. COMPARISON OF REHOSPITALIZATION RATE IN INDIVIDUALS WITH SCHIZOPHRENIA CHANGED FROM PALIPERIDONE PALMITATE TO ORAL ANTIPSYCHOTICS
por: Ju Lee, Bong, et al.
Publicado: (2020)

T236. A PROGRAM TO INCREASE THE APPROPRIATE USE OF LONG-ACTING ANTIPSYCHOTIC MEDICATIONS IN COMMUNITY SETTINGS
por: Velligan, Dawn, et al.
Publicado: (2020)

T23. ANTIPSYCHOTIC EXPOSURE AND STRIATAL FUNCTIONAL CONNECTIVITY IN PSYCHOSIS RELAPSE: A HYPOTHESIS GENERATING STUDY
por: Rubio, Jose, et al.
Publicado: (2020)

T40. GLYCERYL TRINITRATE IN FIRST EPISODE PSYCHOSIS UNMEDICATED WITH ANTIPSYCHOTICS: A RANDOMISED CONTROLLED FEASIBILITY STUDY
por: Merritt, Kate, et al.
Publicado: (2020)

T28. BENEFITS AND HARMS OF ANTIPSYCHOTICS IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Hagi, Katsuhiko, et al.
Publicado: (2020)

T14. HYPOTHALAMIC-PITUITARY-GONADAL AXIS HORMONES IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE OF PSYCHOSIS AND HEALTHY CONTROLS
por: Teresa Pons-Cabrera, Maria, et al.
Publicado: (2020)

T154. WHITE MATTER INTEGRITY, DURATION OF UNTREATED PSYCHOSIS, AND ANTIPSYCHOTIC TREATMENT RESPONSE IN MEDICATION-NAïVE FIRST EPISODE PSYCHOSIS PATIENTS
por: Kraguljac, Nina, et al.
Publicado: (2020)

T207. METABOLIC ADVERSE EFFECTS OF OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS IN THE ADULT POPULATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Bowden, Sylvie, et al.
Publicado: (2020)

T79. BALANCING EFFECTS WITH SIDE-EFFECTS: EXAMINING COMPARATIVE METABOLIC CONSEQUENCES OF 18 ANTIPSYCHOTICS IN TREATMENT OF SCHIZOPHRENIA USING NETWORK META-ANALYSIS
por: Pillinger, Toby, et al.
Publicado: (2020)

T246. RISK FACTORS FOR PSYCHOTIC RELAPSE IN CHRONIC SCHIZOPHRENIA AFTER DOSE-REDUCTION OR DISCONTINUATION OF ANTIPSYCHOTICS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Bogers, Jan, et al.
Publicado: (2020)

T214. ANTIPSYCHOTIC TREATMENT PATTERNS AND EFFECTS DURING THE EARLY YEARS AMONG 316 NEWLY DIAGNOSED PATIENTS WITH SCHIZOPHRENIA FROM THE OPUS TRIAL
por: Albert, Nikolai, et al.
Publicado: (2020)

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2020)

T220. IMPACT OF SECOND-GENERATION ANTIPSYCHOTIC SIDE EFFECTS ON FUNCTIONING FROM A SCHIZOPHRENIA PATIENT PERSPECTIVE: GLOBAL PATIENT CENTERED SURVEY INCLUDING PATIENTS FROM ITALY
por: Weiss, Catherine, et al.
Publicado: (2020)

T38. POSTER PRESENTATION: HAMLETT: HANDLING ANTIPSYCHOTIC MEDICATION, A LONGTERM EVALUATION OF TARGETED TREATMENT A PRAGMATIC SINGLE-BLIND RANDOMISED CONTROLLED TRIAL OF CONTINUATION VERSUS DISCONTINUATION OF PSYCHOTIC MEDICATION
por: van‘t Hag, Erna
Publicado: (2020)

Role of Lipids and Divalent Cations in Membrane Fusion Mediated by the Heptad Repeat Domain 1 of Mitofusin
por: Vlieghe, Anaïs, et al.
Publicado: (2023)

T81. MULTIPLE DRUG USE IN SCHIZOPHRENIA - THE ROLE OF EARLY ENVIRONMENTAL RISK ACCUMULATION AND GENETIC PREDISPOSITION
por: Steixner-Kumar, Agnes, et al.
Publicado: (2020)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

T178. MICROPIPETTE-GUIDED DRUG ADMINISTRATION (MDA) METHOD AS A NOVEL PHARMACOLOGICAL TREATMENT METHOD IN MICE: PRECLINICAL VALIDATION USING RISPERIDONE IN THE MATERNAL IMMUNE ACTIVATION MODEL OF NEURODEVELOPMENTAL DISORDERS
por: Scarborough, Joseph, et al.
Publicado: (2020)

T230. IDENTITY IN THE EARLY STAGES OF PSYCHOSIS: PERSPECTIVES OF CANADIAN EARLY PSYCHOSIS CLINICIANS
por: Ben-David, Shelly, et al.
Publicado: (2020)

T198. CAN AUGMENTED SUBLINGUAL OXYTOCIN DECREASE NEGATIVE SYMPTOMS WITHIN TREATMENT RESISTANT SCHIZOPHRENIC POPULATIONS: A PILOT STUDY
por: Marotta, Rocco, et al.
Publicado: (2020)

Associations of SARS-COV-2 infection during pregnancy with cesarean delivery in an Arizona birth cohort
por: Guinn, Debra, et al.
Publicado: (2022)

T85. LIVING WITH PSYCHOSIS IN LATER LIFE
por: Galletly, Cherrie, et al.
Publicado: (2020)

T2. ADVERSE CHILDHOOD EXPERIENCES IN PEOPLE WITH SCHIZOPHRENIA
por: Klaunig, Mallory, et al.
Publicado: (2020)

T67. TRAUMA IN AFFECTIVE AND NONAFFECTIVE PSYCHOSIS: ASSOCIATIONS AND DISSOCIATIONS WITH COGNITIVE FUNCTIONING IN CHILDHOOD AND ADULTHOOD
por: Mollon, Josephine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qllc1l3ga8uvrgrfb8gj5e0f7g